vs

Side-by-side financial comparison of Stock Yards Bancorp, Inc. (SYBT) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Stock Yards Bancorp, Inc. is the larger business by last-quarter revenue ($104.4M vs $70.6M, roughly 1.5× Viridian Therapeutics, Inc.\DE). Stock Yards Bancorp, Inc. runs the higher net margin — 35.1% vs -49.0%, a 84.1% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 11.7%). Stock Yards Bancorp, Inc. produced more free cash flow last quarter ($154.0M vs $-84.7M).

Community Trust Bancorp is an American regional bank holding company that was founded in 1903 as Pikeville National Bank. The renamed corporation continues to have its headquarters in Pikeville, Kentucky, at the heart of Appalachia. Community Trust Bancorp operates a commercial bank, Community Trust Bank, and a trust company, Community Trust and Investment Company of Lexington.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

SYBT vs VRDN — Head-to-Head

Bigger by revenue
SYBT
SYBT
1.5× larger
SYBT
$104.4M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81946.5% gap
VRDN
81958.1%
11.7%
SYBT
Higher net margin
SYBT
SYBT
84.1% more per $
SYBT
35.1%
-49.0%
VRDN
More free cash flow
SYBT
SYBT
$238.7M more FCF
SYBT
$154.0M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
SYBT
SYBT
VRDN
VRDN
Revenue
$104.4M
$70.6M
Net Profit
$36.6M
$-34.6M
Gross Margin
Operating Margin
45.9%
-56.7%
Net Margin
35.1%
-49.0%
Revenue YoY
11.7%
81958.1%
Net Profit YoY
15.5%
54.9%
EPS (diluted)
$1.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SYBT
SYBT
VRDN
VRDN
Q4 25
$104.4M
Q3 25
$101.5M
$70.6M
Q2 25
$97.8M
Q1 25
$93.5M
Q4 24
$93.5M
Q3 24
$89.8M
Q2 24
$85.7M
Q1 24
$83.3M
Net Profit
SYBT
SYBT
VRDN
VRDN
Q4 25
$36.6M
Q3 25
$36.2M
$-34.6M
Q2 25
$34.0M
Q1 25
$33.3M
Q4 24
$31.7M
Q3 24
$29.4M
Q2 24
$27.6M
Q1 24
$25.9M
Operating Margin
SYBT
SYBT
VRDN
VRDN
Q4 25
45.9%
Q3 25
45.0%
-56.7%
Q2 25
43.9%
Q1 25
44.5%
Q4 24
41.9%
Q3 24
41.2%
Q2 24
41.2%
Q1 24
39.5%
Net Margin
SYBT
SYBT
VRDN
VRDN
Q4 25
35.1%
Q3 25
35.7%
-49.0%
Q2 25
34.8%
Q1 25
35.6%
Q4 24
33.9%
Q3 24
32.7%
Q2 24
32.2%
Q1 24
31.1%
EPS (diluted)
SYBT
SYBT
VRDN
VRDN
Q4 25
$1.24
Q3 25
$1.23
Q2 25
$1.15
Q1 25
$1.13
Q4 24
$1.07
Q3 24
$1.00
Q2 24
$0.94
Q1 24
$0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SYBT
SYBT
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$490.9M
Total DebtLower is stronger
$26.8M
Stockholders' EquityBook value
$1.1B
$503.0M
Total Assets
$9.5B
$577.1M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SYBT
SYBT
VRDN
VRDN
Q4 25
Q3 25
$490.9M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Total Debt
SYBT
SYBT
VRDN
VRDN
Q4 25
$26.8M
Q3 25
$26.8M
Q2 25
Q1 25
$26.8M
Q4 24
$26.8M
Q3 24
$26.8M
Q2 24
$26.8M
Q1 24
$26.8M
Stockholders' Equity
SYBT
SYBT
VRDN
VRDN
Q4 25
$1.1B
Q3 25
$1.0B
$503.0M
Q2 25
$1.0B
Q1 25
$975.5M
Q4 24
$940.5M
Q3 24
$934.1M
Q2 24
$894.5M
Q1 24
$874.7M
Total Assets
SYBT
SYBT
VRDN
VRDN
Q4 25
$9.5B
Q3 25
$9.3B
$577.1M
Q2 25
$9.2B
Q1 25
$9.0B
Q4 24
$8.9B
Q3 24
$8.4B
Q2 24
$8.3B
Q1 24
$8.1B
Debt / Equity
SYBT
SYBT
VRDN
VRDN
Q4 25
0.02×
Q3 25
0.03×
Q2 25
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.03×
Q2 24
0.03×
Q1 24
0.03×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SYBT
SYBT
VRDN
VRDN
Operating Cash FlowLast quarter
$166.0M
$-84.6M
Free Cash FlowOCF − Capex
$154.0M
$-84.7M
FCF MarginFCF / Revenue
147.5%
-120.1%
Capex IntensityCapex / Revenue
11.5%
0.2%
Cash ConversionOCF / Net Profit
4.54×
TTM Free Cash FlowTrailing 4 quarters
$260.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SYBT
SYBT
VRDN
VRDN
Q4 25
$166.0M
Q3 25
$38.2M
$-84.6M
Q2 25
$55.9M
Q1 25
$19.8M
Q4 24
$142.9M
Q3 24
$55.4M
Q2 24
$51.1M
Q1 24
$17.4M
Free Cash Flow
SYBT
SYBT
VRDN
VRDN
Q4 25
$154.0M
Q3 25
$35.2M
$-84.7M
Q2 25
$53.5M
Q1 25
$17.8M
Q4 24
$133.0M
Q3 24
$53.9M
Q2 24
$47.9M
Q1 24
$15.6M
FCF Margin
SYBT
SYBT
VRDN
VRDN
Q4 25
147.5%
Q3 25
34.6%
-120.1%
Q2 25
54.7%
Q1 25
19.1%
Q4 24
142.3%
Q3 24
60.0%
Q2 24
55.9%
Q1 24
18.7%
Capex Intensity
SYBT
SYBT
VRDN
VRDN
Q4 25
11.5%
Q3 25
3.0%
0.2%
Q2 25
2.5%
Q1 25
2.1%
Q4 24
10.5%
Q3 24
1.7%
Q2 24
3.8%
Q1 24
2.2%
Cash Conversion
SYBT
SYBT
VRDN
VRDN
Q4 25
4.54×
Q3 25
1.05×
Q2 25
1.64×
Q1 25
0.59×
Q4 24
4.51×
Q3 24
1.89×
Q2 24
1.85×
Q1 24
0.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons